

12 segment(s) encoding one or more antigenic determinant(s) of HN and/or F glycoproteins of
13 HPIV1 and/or HPIV2 to form a chimeric PIV genome or antigenome, and a transcriptional
14 terminator.

Please cancel claims 7 and 46, without prejudice.

REMARKS

With entry of this amendment, claims 1, 21, 22, 39, 48 and 50 have been amended and claims 7 and 46 canceled without prejudice to more distinctly set forth certain aspects of the invention. These amendments are fully supported by the specification and no new matter has been added to the application.


CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 206-467-9600.

Respectfully submitted,

Dated: March /16 / 00


Jeffrey J. King
Reg. No. 38,515

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (206) 467-9600
Fax: (415) 576-0300

JJK:lmp
SE 5002664 v1